Suomen Akatemia  
 
 
 
 
 
Rahoituspäätös
 
Hakija / Yhteyshenkilö Kantele, Anu
Organisaatio Helsingin yliopistollinen keskussairaala
Tutkimusaihe Suojaava immuunivaste Covid-19 infektiossa: kehitys, kesto, sovellus toipilasplasmahoitona
Päätös 336439
Päätöspvm 24.06.2020
Rahoituskausi 01.01.2020 - 31.12.2022
Rahoitus (€) 1 562 757
   
Hankkeen julkinen kuvaus
Thus far there are neither vaccines to prevent the global health threat SARS-CoV-2, nor medications for treating the disease. In convalescent plasma (CP) therapy, CP obtained from recovered Covid-19 patients is given to patients with an acute Covid-19 infection. Preliminary studies of SARS, MERS and Covid-19 suggest that CP therapy speeds recovery and decreases mortality. Controlled trials are needed to confirm its efficacy. In our CP therapy trial, patients recovered from Covid-19 who have antibodies neutralizing the virus, making it ineffective, are asked to donate blood for preparation of plasma. At hospital, voluntary Covid-19 patients are randomized to receive either CP or regular treatment. The clinical course of their disease is observed. If CP therapy proves effective, arrangements will be established to make it available to all Finnish hospitals. The study is a collaboration between Helsinki University Hospital, University of Helsinki, and Finnish Red Cross Blood Services.